These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20841471)

  • 1. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
    Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Wexler LH; DeLaney TF; Tsokos M; Avila N; Steinberg SM; Weaver-McClure L; Jacobson J; Jarosinski P; Hijazi YM; Balis FM; Horowitz ME
    Cancer; 1996 Aug; 78(4):901-11. PubMed ID: 8756388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
    Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
    Sancéau J; Poupon MF; Delattre O; Sastre-Garau X; Wietzerbin J
    Oncogene; 2002 Oct; 21(50):7700-9. PubMed ID: 12400012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two cases of Ewing's sarcoma originating from the adult rib].
    Ishida S; Akiba Y; Ohosaki Y; Onodera S; Fujita Y; Tagaki S; Shimizu T; Sakai E; Ikushima Y; Saotome K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jun; 29(6):724-8. PubMed ID: 1895588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
    Siddiqui T; Marsh Rde W; Allegra C; Whittaker D; Scarborough M; Gibbs P; Zlotecki R; Reith JD; Drane W
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):499-504. PubMed ID: 20864918
    [No Abstract]   [Full Text] [Related]  

  • 13. Salvage chemotherapy for recurrent Ewing's sarcomas.
    Ozaki T; Sugihara S; Hamada M; Nakagawa Y; Inoue H
    Neoplasma; 1995; 42(1):39-42. PubMed ID: 7617074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
    Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
    Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preoperative adjuvant therapy for primary malignant bone tumors].
    Goto T; Okuma T; Nakada I; Hozumi T; Kondo T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1750-4. PubMed ID: 18030009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment for Ewing's sarcoma.
    Thacker MM; Temple HT; Scully SP
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):319-31. PubMed ID: 15877528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.